Clinical Trial Update: 48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting on 48 weeks of combination therapy for patients with HBeAg-negative chronic hepatitis B infection; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Snippet

Sponsor: Foundation for Liver Research | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED